HSIC logo

Henry Schein, Inc. Stock Price

NasdaqGS:HSIC Community·US$9.4b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

HSIC Share Price Performance

US$83.69
10.54 (14.41%)
US$88.07
Fair Value
US$83.69
10.54 (14.41%)
5.0% undervalued intrinsic discount
US$88.07
Fair Value
Price US$83.69
AnalystConsensusTarget US$88.07
AnalystHighTarget US$104.00

HSIC Community Narratives

·
Fair Value US$88.07 5.0% undervalued intrinsic discount

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook

1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
·
Fair Value US$104 19.5% undervalued intrinsic discount

Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$104
19.5% undervalued intrinsic discount
Revenue
4.16% p.a.
Profit Margin
4.43%
Future PE
19.2x
Price in 2029
US$127.33

Trending Discussion

Updated Narratives

HSIC logo

HSIC: Healthy Dental Trends And Cost Controls Are Expected To Support Balanced Outlook

Fair Value: US$88.07 5.0% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
HSIC logo

Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power

Fair Value: US$104 19.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Fair value with mediocre balance sheet.

1 Risk
2 Rewards

Henry Schein, Inc. Key Details

US$13.4b

Revenue

US$9.2b

Cost of Revenue

US$4.2b

Gross Profit

US$3.8b

Other Expenses

US$395.0m

Earnings

Last Reported Earnings
Mar 28, 2026
Next Reporting Earnings
n/a
3.47
31.19%
2.95%
70.6%
View Full Analysis

About HSIC

Founded
1932
Employees
25000
CEO
Frederick Lowery
WebsiteView website
www.henryschein.com

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Recent HSIC News & Updates

Seeking Alpha Jun 22

Henry Schein: Smile Because The Upside Isn't Over

Summary Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026. Valuation remains attractive relative to peers, supporting a continued 'buy' rating based on industry leadership, growth catalysts, and reasonable multiples. Read the full article on Seeking Alpha
Analysis Article Jun 16

Henry Schein (HSIC) Stock Could Be 7% Undervalued After BTIG Upgrade

BTIG’s recent upgrade of Henry Schein (HSIC), citing solid dental segment trends and cost-saving efforts that support profitability, has drawn fresh attention to the stock and how investors interpret evolving industry pressures. See our latest analysis for Henry Schein. The recent BTIG upgrade comes after a period where Henry Schein’s 1 month share price return of 11.51% and 1 year total shareholder return of 14.60% suggest improving momentum following more modest multi year gains. If this...
Narrative Update Jun 11

HSIC: Dental Demand And Cost Controls Are Expected To Support Balanced Outlook

Analysts have raised their average price target on Henry Schein to $100. They cite recent commentary around generally healthy dental markets, margin gains in Q1 driven by cost reductions, and a view that the stock has found technical support.

Recent updates

No updates